Melfalan Hikma

Melphalan, the active ingredient in Melfalan Hikma, is an alkylating agent presented as an intravenous formulation for intravenous use. It is used in the treatment of certain cancers such as multiple myeloma, ovarian cancer, and malignant melanoma in adult patients.

GNH USA supplies Melfalan Hikma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Melfalan Hikma is an alkylating antineoplastic agent used in the management of specific malignant diseases. - Multiple myeloma: helps control disease progression and improve survival in adult patients. - Ovarian cancer: used as part of combination chemotherapy to reduce tumor burden. - Malignant melanoma: employed in advanced cases to inhibit tumor growth.

Melfalan Hikma may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported during treatment. - Myelosuppression: decreased blood cell counts leading to anemia, neutropenia, or thrombocytopenia. - Fatigue: persistent tiredness affecting daily activities. - Alopecia: hair loss that may be temporary or prolonged. - Mucositis: inflammation of the mouth and gastrointestinal lining. - Diarrhea: loose stools occurring during or after infusion.

Serious or Rare Side Effects: - Severe infection: due to profound neutropenia, increasing risk of sepsis. - Pulmonary toxicity: interstitial pneumonitis or fibrosis presenting with cough and dyspnea. - Renal impairment: acute kidney injury manifested by reduced urine output. - Secondary malignancies: rare development of new cancers after prolonged exposure. - Cardiotoxicity: arrhythmias or myocardial dysfunction in susceptible patients. - Hypersensitivity reactions: rash, fever, or anaphylaxis during infusion.

Before initiating therapy with Melfalan Hikma, several safety considerations should be observed. - Baseline blood counts: obtain complete blood count to assess marrow function. - Renal function: evaluate serum creatinine and calculate clearance for dose adjustment. - Hepatic function: monitor liver enzymes as hepatic impairment may affect metabolism. - Pregnancy risk: avoid use in pregnant women; discuss contraception with women of childbearing potential. - Infection monitoring: watch for signs of febrile neutropenia and treat promptly. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Melfalan Hikma can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Live vaccines: concurrent use may cause severe infection due to immunosuppression. - High-dose radiation therapy: may increase tissue toxicity and delayed healing. - Certain antibiotics (e.g., aminoglycosides): can exacerbate nephrotoxicity.

Moderate Interactions (Monitor Closely): - Antifungal agents (azoles): may affect melphalan metabolism and increase toxicity. - Allopurinol: can potentiate bone marrow suppression. - NSAIDs: may increase risk of renal impairment when combined with melphalan.